Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.89 |
| ▸ | BCL2 | P10415 | 13/20 | 0.89 |
| ▸ | ALB | P02768 | 1/20 | 0.75 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425269 | 0.91 | BCL2L1 (0.74) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL1541023 | 0.89 | BCL2L1 (0.80) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL1541424 | 0.88 | BCL2L1 (0.80) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL3953783 | 0.86 | BCL2L1 (0.82) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL3953785 | 0.86 | BCL2L1 (0.82) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL31384063 | 0.86 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL681275 | 0.86 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL681276 | 0.86 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2953451 | 0.86 | BCL2L1 (0.81) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL1112479 | 0.86 | BCL2L1 (0.67) | BCL2L1BCL2ALBBCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBVIE INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | ABBVIE INC. | 2016-04-14 | — | — | US | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090176785-A1 | METHOD OF TREATING ARTHRITIS | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2L1 953/4885BCL2 520/4885ALB 4422/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885ALB 4701/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885ALB 4701/4885 |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | MMP1, COL2A1, MMP13 | BCL2L1 1304/4885BCL2 147/4885ALB 122/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885ALB 4701/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885ALB 4701/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | BCL2L1 20/4885BCL2 4/4885ALB 4725/4885 |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | BCL2, BAX, BCLAF1 | BCL2L1 7/4885BCL2 1/4885ALB 3484/4885 |
| US-20090176785-A1 | METHOD OF TREATING ARTHRITIS | MMP1, COL2A1, MMP13 | BCL2L1 1304/4885BCL2 147/4885ALB 122/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885ALB 4574/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885ALB 4701/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | BCL2L1 3/4885BCL2 4/4885ALB 3322/4885 |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885ALB 583/4885 |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885ALB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.